- U.S. Centers for Medicare & Medicaid Services (CMS) reimbursement expands access of the FreeStyle Libre 2 system to Medicare patients[1] to better manage their diabetes - The FreeStyle Libre 2 ...

Abbott Laboratories ABT recently announced that its FreeStyle Libre 3 sensor integrated with the mylife Loop solution — building a smart, automated process to deliver insulin based on real-time ...

The FreeStyle Libre 3 system is the latest generation in Abbott (ABT)'s FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the ...

A new study published in US Endocrinology found Abbott’s continuous glucose monitoring system, the FreeStyle Libre, demonstrated significant cost savings for diabetic care compared to traditional ...

Diabetes Care and CamDiab are pleased to announce that Health Canada has approved the use of mylife Loop powered by mylife ...

ABBOTT PARK, Ill., April 8, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the FreeStyle Libre 14 day system, the world's leading 3 continuous glucose monitoring (CGM) technology, can ...

Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...

Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, the world's leading sensor-based glucose monitoring technology, is associated with significant reduction in ...

The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...

In a recent press release from Abbott, they announced FreeStyle® Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having ...

Abbott’s FreeStyle Libre glucose sensor has already been proven to help people with both Type 1 and Type 2 diabetes better manage their blood sugar levels, and a new study demonstrates just how ...

Abbott's (NYSE: ABT) newest sensor-based glucose technology, the FreeStyle Libre 3 Plus* sensor, is now publicly funded in ...